Equillium Valuation Multiples

Equillium Overview

About Equillium

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Founded

2017

HQ

Employees

35

Website

equilliumbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

Net Income: ($24M)

EV

$92M

Valuation Multiples

Multiples.vc

Start free trial

Equillium Financials

Equillium reported last 12-month revenue of —.

In the same LTM period, Equillium generated ($73K) in gross profit and had net loss of ($24M).

Equillium P&L

In the most recent fiscal year, Equillium reported revenue of — and EBITDA of ($24M).

Equillium expects next 12-month revenue of XXX and NTM EBITDA of XXX

Equillium Stock Performance

Equillium has current market cap of $121M, and enterprise value of $92M.

Equillium's stock price is $1.92.

Equillium Valuation Multiples

Equillium trades at (3.9x) EV/EBITDA.

Equillium Financial Valuation Multiples

As of April 11, 2026, Equillium has market cap of $121M and EV of $92M.

Equity research analysts estimate Equillium's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Equillium has a P/E ratio of (5.1x).

Equillium Margins & Growth Rates

Equillium's revenue in the last fiscal year declined by (100%).

Equillium's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Equillium Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Equillium M&A Activity

Equillium acquired XXX companies to date.

Last acquisition by Equillium was on XXXXXXXX, XXXXX. Equillium acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Equillium Investment Activity

Equillium invested in XXX companies to date.

Equillium made its latest investment on XXXXXXXX, XXXXX. Equillium invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).